Sugi Predict

Sugi Predict / Compounds / SCHEMBL349075

SCHEMBL349075

SCHEMBL349075

COc1cc(Br)c(C=O)c(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 4/20 0.65
▸ PRKDC P78527 1/20 0.55
▸ LMNA P02545 2/20 0.51
▸ ALDH1A1 P00352 4/20 0.48
▸ MAOA P21397 2/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.45
▸ CYP1A1 P04798 3/20 0.44
▸ CYP1B1 Q16678 3/20 0.44
▸ CYP1A2 P05177 3/20 0.44
▸ TDP1 Q9NUW8 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ TRIM24 O15164 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALDH5A1 P51649 1/20 0.39
▸ ABAT P80404 1/20 0.39
▸ TRIM33 Q9UPN9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30230047 1.00 ERN1 (0.65) ERN1PRKDCLMNAALDH1A1MAOA
2,4,6-Trimethoxybenzaldehyde SCHEMBL34873 0.87 ERN1 (0.74) ERN1PRKDCLMNAALDH1A1MAOA
2,4,6-Trimethoxybenzaldehyde SCHEMBL28687257 0.85 ERN1 (0.71) ERN1PRKDCLMNAALDH1A1MAOA
SCHEMBL16269455 0.84 PRKDC (0.55) ERN1PRKDCLMNAALDH1A1CYP1A2
2,4,6-Trimethoxybenzaldehyde SCHEMBL28687256 0.83 ERN1 (0.75) ERN1PRKDCLMNAALDH1A1MAOA
SCHEMBL12581710 0.82 PRKDC (0.53) ERN1PRKDCLMNAALDH1A1MAOA
SCHEMBL16632430 0.81 PRKDC (0.52) ERN1PRKDCLMNAALDH1A1CYP1A2
SCHEMBL31673953 0.81 PRKDC (0.52) ERN1PRKDCLMNAALDH1A1MAOA
SCHEMBL12311288 0.80 ERN1 (0.65) ERN1PRKDCLMNAALDH1A1ABCG2
SCHEMBL4099200 0.80 ERN1 (0.65) ERN1PRKDCLMNAALDH1A1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111116493-B Method for preparing Apabetalone, intermediate and preparation method of intermediate 上海工程技术大学 2021-07-27 — — CN claimed
CN-111116493-A Method for preparing Apabetalone, intermediate and preparation method of intermediate 上海工程技术大学 2020-05-08 — — CN claimed
CN-108218798-B Preparation method of Apabetalone 南方医科大学 2020-04-24 — — CN claimed
CN-109896943-A A kind of chemical preparation process of cajanin and its analogue 暨南大学 2019-06-18 — — CN claimed
CN-108218798-A The preparation method of Apabetalone 南方医科大学 2018-06-29 — — CN claimed
US-20240365736-A1 COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL OERTH BIO LLC (US) 2024-11-07 — — US disclosed
WO-2024220626-A1 SMALL MOLECULE MODULATORS OF OGG1 AZKARRA THERAPEUTICS, INC. (US) 2024-10-24 — — WO disclosed
EP-4395549-A1 COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL Oerth Bio LLC (US) 2024-07-10 — — EP disclosed
US-11976058-B2 Aromatic derivatives, preparation methods, and medical uses thereof BIOARDIS LLC (US) 2024-05-07 — — US disclosed
CN-115710202-B Preparation method and application of apataone key intermediate 江西同和药业股份有限公司 2024-05-03 — — CN disclosed
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway REATA PHARMACEUTICALS, INC (US) 2023-11-28 — — US disclosed
WO-2023034411-A1 COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL OERTH BIO LLC (US) 2023-03-09 — — WO disclosed
US-8343944-B2 Trisubstituted boron-containing molecules ANACOR PHARMACEUTICALS, INC. (US) 2013-01-01 — — US disclosed
EP-2458995-A1 TRISUBSTITUTED BORON-CONTAINING MOLECULES Anacor Pharmaceuticals, Inc. (US) 2012-06-06 — — EP disclosed
US-20120015905-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. 2012-01-19 — — US disclosed
US-8053440-B2 Compounds for the prevention and treatment of cardiovascular diseases Resverlogix Corporation (CA) 2011-11-08 — — US disclosed
US-20110136763-A1 TRISUBSTITUTED BORON-CONTAINING MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-20110136763-A1 TRISUBSTITUTED BORON-CONTAINING MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-20110136763-A1 TRISUBSTITUTED BORON-CONTAINING MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-20080188467-A1 To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists HEPALINK (HONG KONG) LIMITED (HK) 2008-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11976058-B2 Aromatic derivatives, preparation methods, and medical uses thereof FGFR4, FGFR3, FGFR1 ERN1 4084/4885PRKDC 408/4885LMNA 3507/4885
US-20110136763-A1 TRISUBSTITUTED BORON-CONTAINING MOLECULES BCL6B, BCL6, BLK ERN1 3820/4885PRKDC 4865/4885LMNA 4563/4885
US-20240365736-A1 COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL CRBN, LTN1, CBL ERN1 2113/4885PRKDC 1990/4885LMNA 674/4885
US-20120015905-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 ERN1 1054/4885PRKDC 4786/4885LMNA 489/4885
US-20080188467-A1 To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists APOB, LDLR, APOL1 ERN1 787/4885PRKDC 4471/4885LMNA 993/4885
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway HSPA2, HSP90AB2P, HSF1 ERN1 1753/4885PRKDC 2477/4885LMNA 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.